These mechanistic insights have enabled the successful clinical translation of mTOR inhibitors (rapamycin, everolimus) in TSC-associated epilepsy, demonstrating significant seizure frequency reduction (50% responder rate) and cognitive improvement (33, 34). The gene discussed is MTOR; the disease is epilepsy.